Loading...

MIRA MIRA PHARMACEUTICALS INC Management Changes 8-K Filing

MR P

MR

MIRA PHARMACEUTICALS INC

(MIRA)

2026 8-K

Management Change

License Agreement Update

License Agreement Update

Positive Trial Results

Research Publication Announced

Mira-55 Study Results

Phase 1 Trial Update

Clinical Trial Update

CEO Incentive Awards

Stock Offering Increase

Clinical Trial Update

Stock Offering Completed

Mira-55 Success

Company Acquisition

Phase 1 Results

Positive PTSD Data

Shareholder Meeting Results

Ketamir-2 Trial Update

Clinical Trials

Clinical Trials

Equity Offerings

Asset Acquisitions

Asset Acquisitions

Asset Acquisitions

Clinical Trials

Product Expansion

Positive Study Results

Clinical Trial Launch

Acquisition Agreement

Product Development

Clinical Trial Approval

Accounting Firm Change

Drug Safety Validation

Management Changes

Clinical Trial Announcement

Ketamir-2 Efficacy

Ketamine Study Results

Annual Meeting Results

Drug Development Update

Preclinical Success

Compliance Regained

Preclinical Study Data on K...

Preclinical Success

Delisting Notice

Changes in Management

Board Restructuring and Res...

Discovery of New Molecule

Resignation of Director

Appointment and Resignation

License Agreement and Loan ...

Appointment and Resignation...

Amendment to Employment Agr...

Public Offering

External Links:

Mira Pharmaceuticals appointed Andriy Mushak as Fractional Chief Financial Officer effective June 6, 2026, replacing Alan Weichselbaum, whose departure was amicable. Mushak, a CPA with over 20 years of experience, will be compensated $6,000 monthly for his services.

AI Assistant

MIRA PHARMACEUTICALS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.